Expressed hypervariable polymorphism of apolipoprotein (a)

M I Kamboh, R E Ferrell, B A Kottke, M I Kamboh, R E Ferrell, B A Kottke

Abstract

Elevated plasma lipoprotein (a) (LP(a] levels are an independent predictor of the development of premature atherosclerosis in humans. The LP(a) particle consists of two disulfide-linked proteins, apolipoprotein (APO) B and APO(a). The APO(a) is a highly glycosylated protein which carries the LP(a) antigen. Genetic polymorphism in the APO(a) molecule has been reported, and, depending on the sensitivity of the method used, 6-11 alleles at the APO(a) structural locus have been documented in the literature. In this investigation, we have used a high-resolution SDS-agarose electrophoresis method followed by immunoblotting to screen APO(a) polymorphism in 54 families with 130 offspring. This method identified a total of 23 different APO(a) isoforms, and their genetic basis was confirmed in families. In addition to the detectable products of 23 APO(a) alleles, the family data predict the existence of a "null" allele. Of the total 270 individuals tested, 209 (77.4%) revealed double-banded phenotypes and 61 (22.6%) revealed single-banded phenotypes. In the unrelated sample of 140 individuals, however, 114 (81.4%) and 26 (18.6%) had double- and single-banded phenotypes, respectively. When the segregation pattern of single-banded phenotypes in the unrelated sample was followed in families, only nine (6.4%) were found to be true homozygotes, and the remaining 17 (12.2%) were classified as heterozygotes for the null allele. Of the 276 possible phenotypes predicted for 23 alleles in a large population, we observed 115 (42%) phenotypes in our restricted sample. On the basis of our results from the family data, we hypothesize the existence of at least 24 alleles, including a null allele, at the APO(a) structural locus.(ABSTRACT TRUNCATED AT 250 WORDS)

References

    1. Ann Hum Genet. 1974 Jul;38(1):47-56
    1. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4171-4
    1. Am J Med Genet. 1983 Oct;16(2):179-88
    1. Genet Epidemiol. 1985;2(2):113-21
    1. Genet Epidemiol. 1986;3(1):53-5
    1. Atherosclerosis. 1986 Feb;59(2):199-204
    1. J Biol Chem. 1986 Jul 5;261(19):8712-8
    1. Circulation. 1986 Oct;74(4):758-65
    1. JAMA. 1986 Nov 14;256(18):2540-4
    1. Atherosclerosis. 1986 Dec;62(3):249-57
    1. Neurology. 1987 Mar;37(3):513-5
    1. Proc Natl Acad Sci U S A. 1987 May;84(10):3224-8
    1. Nature. 1987 Jul 2-8;328(6125):82-4
    1. J Clin Invest. 1987 Aug;80(2):458-65
    1. Nature. 1987 Nov 12-18;330(6144):113-4
    1. Nature. 1987 Nov 12-18;330(6144):132-7
    1. Hum Genet. 1988 Jan;78(1):41-6
    1. Hum Genet. 1988 Jan;78(1):47-50
    1. Biol Chem Hoppe Seyler. 1987 Dec;368(12):1533-44
    1. Hum Genet. 1988 May;79(1):80-2
    1. Biochemistry. 1989 Mar 21;28(6):2374-7
    1. J Lipid Res. 1989 Apr;30(4):549-58
    1. Science. 1989 Nov 17;246(4932):904-10
    1. Clin Chem. 1990 Jan;36(1):20-3
    1. Biochemistry. 1990 Jan 23;29(3):640-4
    1. J Lipid Res. 1990 Apr;31(4):603-13
    1. Arteriosclerosis. 1990 Sep-Oct;10(5):672-9
    1. BMJ. 1990 Dec 1;301(6763):1248-51
    1. Acta Pathol Microbiol Scand. 1963;59:369-82
    1. Lancet. 1988 May 14;1(8594):1070-3
    1. Arteriosclerosis. 1988 May-Jun;8(3):212-6
    1. Arteriosclerosis. 1988 Jul-Aug;8(4):398-401
    1. Am J Hum Genet. 1989 Jan;44(1):124-39
    1. Hum Genet. 1989 Jan;81(2):149-52
    1. Genomics. 1988 Oct;3(3):230-6
    1. J Biol Chem. 1989 Apr 15;264(11):6013-6
    1. Hum Genet. 1989 Apr;82(1):73-8
    1. Nature. 1989 May 25;339(6222):301-3
    1. Nature. 1989 May 25;339(6222):303-5
    1. Proc Natl Acad Sci U S A. 1989 May;86(10):3847-51
    1. J Lipid Res. 1977 May;18(3):331-8

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever